Spots Global Cancer Trial Database for blood cancer
Every month we try and update this database with for blood cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation | NCT05873205 | Blood Cancer Refractory Immu... | Isatuximab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation | NCT05873205 | Blood Cancer Refractory Immu... | Isatuximab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00519090 | Myelogenous Leu... | Imatinib Nilotinib (AMN1... | 18 Years - | Novartis | |
| Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy | NCT04390542 | Blood Cancer | Psychoeducation | 18 Years - | Case Comprehensive Cancer Center | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors | NCT00186225 | Blood Cancer Blood and Marro... | ablative alloge... | 4 Weeks - 50 Years | Stanford University | |
| Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention | NCT06168825 | Cancer Breast Cancer Brain Cancer Central Nervous... Colorectal Canc... Esophageal Canc... Gynecologic Can... Head and Neck C... Gastrointestina... Genitourinary C... Melanoma Blood Cancer Lung Cancer Acceptance and ... Mind-Body Thera... Psychosocial In... | Mind Over Matte... | 18 Years - | Inova Health Care Services | |
| Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies | NCT05391490 | Blood Cancer | KCAT19 T cells | 16 Years - 65 Years | University College, London | |
| TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD | NCT00185796 | Myeloproliferat... Blood Cancer Myelodysplastic... | Total Lymphoid ... Anti-Thymocyte ... | 49 Years - 75 Years | Stanford University | |
| Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors | NCT00962494 | Blood Cancer Breast Cancer Prostatic Neopl... Colorectal Neop... Neoplasms | Cancer: Thrivin... | 19 Years - | Stanford University | |
| PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | NCT01131247 | Chronic Lymphoc... | ofatumumab + be... | 18 Years - | Nevada Cancer Institute | |
| A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers | NCT04272203 | Acute Myeloid L... Non Small Cell ... Cancer | ABBV-184 | 18 Years - | AbbVie | |
| A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) | NCT00230321 | Blood Cancer Myelodysplastic... Myelodysplastic... | Darbepoetin alf... | 18 Years - | Stanford University | |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00519090 | Myelogenous Leu... | Imatinib Nilotinib (AMN1... | 18 Years - | Novartis | |
| Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | NCT05745285 | Leukemia Lymphoma Myeloma Myelodysplastic... Myeloproliferat... | LLS Program | 18 Years - | University of Miami | |
| Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies | NCT05391490 | Blood Cancer | KCAT19 T cells | 16 Years - 65 Years | University College, London | |
| Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy | NCT00790036 | Diffuse Large B... | Everolimus Everolimus Plac... | 18 Years - | Novartis | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| Therapeutic Education in Physical Activity (ETAF) | NCT03403075 | Hematologic Neo... | ETAF Usual care | 18 Years - | Arcispedale Santa Maria Nuova-IRCCS | |
| Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors | NCT00962494 | Blood Cancer Breast Cancer Prostatic Neopl... Colorectal Neop... Neoplasms | Cancer: Thrivin... | 19 Years - | Stanford University | |
| Better Leukemia Diagnostics Through AI (BELUGA) | NCT04466059 | Hematologic Mal... Leukemia Minimal Residua... Lymphoma Blood Cancer | Automated AI-Gu... | 18 Years - | Munich Leukemia Laboratory | |
| Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies | NCT05148806 | Solid Organ Tra... Autoimmune Dise... Haematological ... | self-administer... | 12 Years - | Imperial College London | |
| A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies | NCT01957579 | Blood Cancer Advanced B Cell... | MEDI-551 | 20 Years - 130 Years | AstraZeneca | |
| Central Nervous System Disorders Following Hematopoietic Stem Cell Transplantation | NCT04737785 | Central Nervous... Central Nervous... Infectious Dise... Blood Disease Blood Cancer Infection | - | European Society for Blood and Marrow Transplantation | ||
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies | NCT00185640 | Blood Cancer Leukemia | Cyclosporine Anti-thymocyte ... Mycophenolate m... Filgrastim Total Lymphoid ... | 50 Years - 70 Years | Stanford University | |
| TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD | NCT00185796 | Myeloproliferat... Blood Cancer Myelodysplastic... | Total Lymphoid ... Anti-Thymocyte ... | 49 Years - 75 Years | Stanford University | |
| Allogeneic Transplantation From Related Haploidentical Donors | NCT00185692 | Blood Cancer Leukemia Graft Versus Ho... Malignancy CLL NHL Hodgkin's Disea... MDS | non-myeloablati... Anti-Thymocyte ... Cyclosporine Mycophenolate M... G-CSF Solumedrol Acetaminophen Diphenydramine Hydrocortisone | 12 Months - | Stanford University | |
| Immune Profiling for Cancer Immunotherapy Response | NCT06116032 | Cancer Tumor, Solid Hematologic Mal... Blood Cancer | Methylation Cyt... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Resiliency in Older Adults Undergoing Bone Marrow Transplant | NCT04188678 | Leukemia Lymphoma Blood Cancer Myelodysplastic... Acute Myelogeno... Non-Hodgkins Ly... | Bone Marrow Tra... | 60 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL | NCT02361346 | Non-Hodgkin's B... Leukemia, Lymph... Small Lymphocyt... Diffuse Large B... Blood Cancer Hematological M... | MT-3724 Phase 1 MT-3724 Phase 2 | 18 Years - | Molecular Templates, Inc. | |
| Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients | NCT05709522 | Brain Tumor, Pe... Blood Cancer | Neurocognitive ... | 5 Years - 21 Years | Aga Khan University | |
| Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) | NCT00750737 | Invasive Fungal... Hematologic Mal... | Posaconazole ABLC | 18 Years - | M.D. Anderson Cancer Center | |
| Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients | NCT00824993 | Hematological M... | Ibandronate Vitamin Supplem... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | NCT03787498 | Relapsed Acute ... Refractory Acut... High-risk Myelo... | PLX2853 | 18 Years - | Opna Bio LLC | |
| Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention | NCT06168825 | Cancer Breast Cancer Brain Cancer Central Nervous... Colorectal Canc... Esophageal Canc... Gynecologic Can... Head and Neck C... Gastrointestina... Genitourinary C... Melanoma Blood Cancer Lung Cancer Acceptance and ... Mind-Body Thera... Psychosocial In... | Mind Over Matte... | 18 Years - | Inova Health Care Services | |
| Predictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy. | NCT05450367 | Blood Cancer | Data collection | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies | NCT00185640 | Blood Cancer Leukemia | Cyclosporine Anti-thymocyte ... Mycophenolate m... Filgrastim Total Lymphoid ... | 50 Years - 70 Years | Stanford University | |
| Early Integration of Palliative and Supportive Care in Cellular Therapy | NCT05190653 | Leukemia Lymphoma Multiple Myelom... Blood Cancer Stem Cell Trans... Chimeric Antige... | Early palliativ... | 18 Years - | Alberta Health Services, Calgary | |
| Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy | NCT00790036 | Diffuse Large B... | Everolimus Everolimus Plac... | 18 Years - | Novartis | |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | NCT02223052 | Hematological N... Non-Hodgkin's L... Hodgkin's Lymph... Lymphoma Multiple Myelom... Acute Myeloid L... Leukemia Myelodysplastic... Neoplasms Melanoma Breast Cancer Metastatic Brea... Non-Small Cell ... Small Cell Lung... Renal Cell Carc... Glioblastoma Mu... Osteosarcoma Sarcoma Thyroid Cancer Genitourinary | CC-486 Vidaza | 18 Years - | Celgene | |
| Rehabilitation Needs of the Malaysian Haematological Cancer Survivors | NCT04236063 | Haematological ... Leukemia, Acute Lymphoma Myeloma Multipl... Blood Cancer Quality of Life | WHODAS 2.0 Ques... | 18 Years - 80 Years | University of Malaya | |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | NCT06119685 | NHL Multiple Myelom... Blood Cancer Refractory Non-... Relapsed Non-Ho... Refractory Mult... Relapsed Multip... | IDP-023 Rituximab Daratumumab Interleukin-2 Cyclophosphamid... Fludarabine Mesna | 18 Years - | Indapta Therapeutics, INC. | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| Rehabilitation Needs of the Malaysian Haematological Cancer Survivors | NCT04236063 | Haematological ... Leukemia, Acute Lymphoma Myeloma Multipl... Blood Cancer Quality of Life | WHODAS 2.0 Ques... | 18 Years - 80 Years | University of Malaya | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| Better Leukemia Diagnostics Through AI (BELUGA) | NCT04466059 | Hematologic Mal... Leukemia Minimal Residua... Lymphoma Blood Cancer | Automated AI-Gu... | 18 Years - | Munich Leukemia Laboratory | |
| Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy | NCT05646576 | Hematologic Mal... Blood Cancer Lymphoma Leukemia Multiple Myelom... | Palliative Care Usual Care | 18 Years - | Massachusetts General Hospital | |
| Predictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy. | NCT05450367 | Blood Cancer | Data collection | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients | NCT05709522 | Brain Tumor, Pe... Blood Cancer | Neurocognitive ... | 5 Years - 21 Years | Aga Khan University | |
| Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS | NCT05593185 | Acute Myeloid L... Myelodysplastic... | Galinpepimut-S | 18 Years - | Sellas Life Sciences Group | |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | NCT06119685 | NHL Multiple Myelom... Blood Cancer Refractory Non-... Relapsed Non-Ho... Refractory Mult... Relapsed Multip... | IDP-023 Rituximab Daratumumab Interleukin-2 Cyclophosphamid... Fludarabine Mesna | 18 Years - | Indapta Therapeutics, INC. | |
| A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00471497 | Myelogenous Leu... | nilotinib imatinib | 18 Years - | Novartis | |
| Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | NCT05745285 | Leukemia Lymphoma Myeloma Myelodysplastic... Myeloproliferat... | LLS Program | 18 Years - | University of Miami | |
| Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies | NCT05148806 | Solid Organ Tra... Autoimmune Dise... Haematological ... | self-administer... | 12 Years - | Imperial College London | |
| CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) | NCT06345027 | Leukemia, Myelo... Leukemia, B-cel... Leukemia, T-Cel... Lymphoma | Treatment Arm A | - 75 Years | Baylor College of Medicine | |
| Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy | NCT04390542 | Blood Cancer | Psychoeducation | 18 Years - | Case Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
